Lapix Therapeutics Inc. — Form D/A
Lapix Therapeutics Inc. of Cambridge, MA, a company, filed a Form D amendment with the SEC on 2025-02-10. The offering totals $6.0M, of which $5.5M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2025-02-10
- Form: D/A
- Accession: 0001947620-25-000001
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $6.0M
- Amount sold: $5.5M
- Remaining: $479K
- Investors: 25
- Date of first sale: 2024-08-02
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-521850
Issuer
- Name: Lapix Therapeutics Inc.
- CIK: 0001947620
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2019
- Address: 271 Cambridge St., 2nd Floor, Cambridge, MA, 02141
- Phone: 8582264717
Officers, directors & promoters (7)
| Name | Role | Location |
|---|
| Francisco Leon | Director | Philadelphia, PA |
| Anas Fathallah | Director | Cambridge, MA |
| Anas Fathallah | Executive Officer | Cambridge, MA |
| Anthony Gibney | Director | Cambridge, MA |
| Jason Norris | Director | Cambridge, MA |
| Jason Norris | Executive Officer | Cambridge, MA |
| Henry McKinnell | Director | Cambridge, MA |
Other filings by this issuer (4)
More